JNJ Johnson & Johnson
Company Analysis
Latest News
Johnson & Johnson Q3 2026 Earnings Preview: What Analysts Expect on October 13, 2026
Consensus estimates for Johnson & Johnson's third quarter of 2026 call for revenue of $25.40 billion and adjusted EPS of $2.66, as the stock trades near...
J&J Wins Injunction Blocking U.S. Simponi Biosimilar Launch
Johnson & Johnson’s Janssen unit secured a preliminary injunction blocking the U.S. launch of the first biosimilars for its immunology drugs Simponi and...
J&J Reports 50% Five-Year Treatment-Free Remission With CARVYKTI
Johnson & Johnson reported long-term results for CARVYKTI® (ciltacabtagene autoleucel) from the Phase 2 CARTITUDE-2 study. The findings showed that a single...
Johnson & Johnson Analysis Suggests Myeloma Combo May Normalize Mortality Risk
Johnson & Johnson released a new model-based analysis of its Phase 3 MajesTEC-3 study. The analysis suggests its combination therapy for multiple myeloma could...
J&J Hits Bipolar Goal with CAPLYTA, Reducing Symptoms Within Three Days
Johnson & Johnson reported positive topline results from a pivotal Phase 3 study of CAPLYTA (lumateperone). The trial evaluated the drug for treating manic...
🟢 Johnson & Johnson is trading 3.02% up in after-hours trading after CHMP recommended TECVAYLI expansion
Johnson & Johnson is trading 3.02% up at $278.15 in after-hours trading after the European Medicines Agency’s CHMP recommended expanding TECVAYLI approval for...
J&J's TECVAYLI Gets EU Panel Backing for Expanded Myeloma Use
Johnson & Johnson announced the CHMP recommended expanding approval for its cancer drug, TECVAYLI (teclistamab). The recommendation targets adult patients with...
Johnson & Johnson Rybrevant sets survival record for rare lung cancer
Johnson & Johnson announced final Phase 3 PAPILLON study data for its drug RYBREVANT (amivantamab-vmjw). The trial evaluated RYBREVANT combined with...
J&J Nears $20 Billion Orthopedics Sale to Apollo, Streamlining Operations
Johnson & Johnson is in advanced talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management. The transaction is valued at nearly $20 billion....
Johnson & Johnson hits 52-week high, UBS raises target to $320
Johnson & Johnson shares reached a new 52-week high on Wednesday. UBS increased its price target for the stock to $320 from $280. The share price rose...
Johnson & Johnson Offsets Stelara Losses With New Drug Sales
Johnson & Johnson navigates the loss of exclusivity for its blockbuster immunology drug, Stelara. Stelara sales declined by $913 million in the second quarter...
🟢 Johnson & Johnson is trading 3.13% up today as healthcare stocks gain
Johnson & Johnson is trading at 3.13% up now at $279.69 after healthcare-sector strength. • Healthcare stocks gained 1.37% during regular trading. • No new...
Johnson & Johnson's Stelara Wins FDA Approval for Pediatric Ulcerative Colitis
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's Stelara (ustekinumab) injection for moderately to severely active ulcerative colitis...
Robert Olstein's fund exits Johnson & Johnson stake
Value investor Robert Olstein of Olstein Capital Management has completely sold off his firm's stake in Johnson & Johnson, according to a recent quarterly...
Johnson & Johnson's Psoriasis Pill Icotyde Gains Approval in China
China's drug regulator approved Johnson & Johnson's oral medication, Icotyde (icotrokinra), for moderate-to-severe plaque psoriasis. The approval offers a new...
Johnson & Johnson wins FDA approval for IMAAVY, first-ever rare blood treatment
Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA)....
Farallon Capital more than doubles its Johnson & Johnson stake
Farallon Capital Management significantly increased its stake in Johnson & Johnson by over 175%, bringing its total holdings to 408,000 shares. According to...
Johnson & Johnson Secures EU Approval for TECVAYLI, Targeting Second-Line Myeloma
The European Commission approved an expanded indication for Johnson & Johnson’s TECVAYLI (teclistamab) in combination with daratumumab. This treatment targets...
Trump taps Heidi Overton for FDA, following 3,000 staff departures
President Donald Trump expects to nominate Heidi Overton as the next Food and Drug Administration (FDA) commissioner. Overton currently serves as a top aide at...
🟢 Johnson & Johnson is trading 3.12% up today as investors rotate toward defensive healthcare stocks
Johnson & Johnson is trading 3.12% up now at $270.56, as investors rotate toward defensive healthcare stocks. - The healthcare sector is up 1.59%, while the...